Jefferies' Clients, Employees and Shareholders Contribute $9,250,000 to Over 85 Charities for Coronavirus Relief in Memory of Peg Broadbent
Jefferies announced today a total donation to over 85 different charities of $9.25 million as a result of a firmwide global effort to raise money to honor the memory of their late CFO Peg Broadbent, who was a victim of this terrible disease.
Through the firm’s Global Coronavirus Relief Charity Day held May 27th, Jefferies’ clients helped to generate $7.65 million in donated net trading commissions. In addition, Jefferies as a firm will donate $1 million directly, and voluntary donations from Jefferies’ 3,822 employees totaled $600,000.
“We could not be prouder of our entire Jefferies family for raising $9.25 million and are greatly appreciative of the incredible partnership our clients have shown us in supporting our fight against Covid-19. The full $9.25 million will be wired today and go to direct relief efforts at over 85 worthy global charities who are each in the front lines helping those most impacted by the Coronavirus global pandemic. We went broadly to a large number of charities globally as this is truly a tragedy that affects all of us and, in particular, those who are most disadvantaged and in the greatest need.
The charities selected are both big and small and represent everything from food banks, child care services, assistance with PPE and other medical supplies, support for front line medical workers, assistance for afflicted military personnel, local teen centers, support for police and fire, workforce training and re-training and many other worthy areas that are most in need. We thank our employees and clients for aiding in the selection of many of these remarkable charities.
Finally, all of us at Jefferies would like to thank all the dedicated professionals working tirelessly on the front line to help those in need. They are the true heroes whom we are honored to help in Peg’s name.”
Contributions in the following amounts will be immediately distributed to these respected organizations:
|
NYC Mayor’s Fund | Peg’s Cure |
|
$ 150,000 |
|
All Hands and Hearts |
|
$ 150,000 |
|
American Heart Association |
$ 150,000 |
|
|
Bowery Mission |
$ 150,000 |
|
|
Hackensack Meridian Health Foundation |
$ 150,000 |
|
|
Houston Police Foundation |
|
$ 150,000 |
|
International Rescue Committee |
|
$ 150,000 |
|
Robin Hood Foundation |
|
$ 150,000 |
|
Strive |
|
$ 150,000 |
|
The Bass Foundation |
|
$ 150,000 |
|
World Central Kitchen |
|
$ 150,000 |
|
We Can #TogetherFromHome |
|
$ 100,000 |
|
Achievement First |
|
$ 100,000 |
|
Aktion Deutschland Hilft |
|
$ 100,000 |
|
Alzheimer’s Association |
|
$ 100,000 |
|
Ambitious About Autism |
|
$ 100,000 |
|
Barnardo’s |
$ 100,000 |
|
|
BMS Family Health and Wellness Center |
|
$ 100,000 |
|
Bob Woodruff Foundation |
|
$ 100,000 |
|
Boys & Girls Clubs of the Austin Area |
|
$ 100,000 |
|
Brewers Community Foundation |
|
$ 100,000 |
|
Buttle UK |
|
$ 100,000 |
|
Central Texas Food Bank |
|
$ 100,000 |
|
Chelsea and Westminster Hospital NHS Foundation Trust |
|
$ 100,000 |
|
Chrysalis |
$ 100,000 |
|
|
City Harvest |
$ 100,000 |
|
|
Citymeals on Wheels |
|
$ 100,000 |
|
Columbia Children's Hospital |
|
$ 100,000 |
|
Community Food Bank of New Jersey |
|
$ 100,000 |
|
Covenant House |
|
$ 100,000 |
|
Doctors Without Borders |
|
$ 100,000 |
|
East High – EOP (Education Partnership Organization) |
|
$ 100,000 |
|
Elmhurst Hospital Charity |
|
$ 100,000 |
|
Family Promise of Bergen County |
|
$ 100,000 |
|
FarmLink |
|
$ 100,000 |
|
Feeding America |
|
$ 100,000 |
|
Food Bank For New York City |
|
$ 100,000 |
|
Foodlink |
|
$ 100,000 |
|
Habitat for Humanity Japan |
|
$ 100,000 |
|
Hance Family Foundation |
|
$ 100,000 |
|
Humanity & Inclusion |
|
$ 100,000 |
|
Hunger Free America |
|
$ 100,000 |
|
Imperial Health Charity |
|
$ 100,000 |
|
Kids in Crisis |
|
$ 100,000 |
|
Kohka Foundation |
|
$ 100,000 |
|
Lahey Clinic Foundation |
|
$ 100,000 |
|
Mail Force Charity |
|
$ 100,000 |
|
Martha’s Table |
|
$ 100,000 |
|
Médecins Sans Frontières |
|
$ 100,000 |
|
Memorial Hermann Foundation |
|
$ 100,000 |
|
My Sister's Place |
|
$ 100,000 |
|
National Emergencies Trust |
|
$ 100,000 |
|
Navajo Nation Covid-19 Relief Fund |
|
$ 100,000 |
|
Nazareth Housing |
|
$ 100,000 |
|
Neighbourly Community Fund |
|
$ 100,000 |
|
NHS Charities Together |
|
$ 100,000 |
|
Northwell Health's COVID-19 Emergency Fund |
|
$ 100,000 |
|
NYU Langone |
|
$ 100,000 |
|
Off Their Plate |
|
$ 100,000 |
|
Oxfam India |
|
$ 100,000 |
|
Philippine Disaster Resilience Foundation |
|
$ 100,000 |
|
Red Hook Initiative |
|
$ 100,000 |
|
Rosetree Trust |
|
$ 100,000 |
|
Royal College of Nursing Foundation |
|
$ 100,000 |
|
RVNAhealth |
|
$ 100,000 |
|
Second Harvest |
|
$ 100,000 |
|
Sempre Con Voi (Always with You) |
|
$ 100,000 |
|
St Michael’s House |
|
$ 100,000 |
|
TBD 1 |
|
$ 100,000 |
|
TBD 2 |
|
$ 100,000 |
|
TBD 3 |
|
$ 100,000 |
|
TCF Bank |
|
$ 100,000 |
|
The Care Workers Charity |
|
$ 100,000 |
|
The River Fund New York |
|
$ 100,000 |
|
The United Way of Central Indiana COVID-19 Relief Fund |
|
$ 100,000 |
|
The World Health Organization (WHO) |
|
$ 100,000 |
|
Trinity's Services & Food for the Homeless |
|
$ 100,000 |
|
The Trussell Trust |
|
$ 100,000 |
|
UNICEF |
|
$ 100,000 |
|
UR Medicine Home Care’s Meals on Wheels |
|
$ 100,000 |
|
URMC COVID-19 Emergency Fund |
|
$ 100,000 |
|
Valpo Surf Project, Inc. |
|
$ 100,000 |
|
Volunteers of Legal Service |
|
$ 100,000 |
|
Our Dream Their Smile |
|
$ 100,000 |
|
West Side Campaign Against Hunger |
|
$ 100,000 |
|
Women United in Philanthropy |
|
$ 100,000 |
|
Women's Center of Greater Danbury |
|
$ 100,000 |
|
|
|
|
Jefferies Group LLC is the largest independent, global, full-service investment banking firm headquartered in the U.S. Focused on serving clients for nearly 60 years, Jefferies is a leader in providing insight, expertise and execution to investors, companies and governments. Our firm provides a full range of investment banking, advisory, sales and trading, research and wealth management services across all products in the Americas, Europe and Asia. Jefferies Group LLC is a wholly owned subsidiary of Jefferies Financial Group Inc. (NYSE: JEF), a diversified financial services company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005663/en/
Contact information
Richard Khaleel, +1 212 284 2556, rkhaleel@jefferies.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
